# US 2003/0170683 A1 · Formin-2 nucleic acids and polypeptides and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0170683 A1
- Document ID: US20030170683A1
- Status: Published application
- Kind: A1
- Application number: 10/308,485
- Filed: 2002-12-03
- Published: 2003-09-11
- Earliest claimed: 2000-04-13
- Inventors: Philip Leder; Benjamin Leader
- Web page: https://patentgrep.com/patent/US20030170683A1

## CPC

- C07K 14/47: from mammals
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The invention features methods and reagents for diagnosing and treating recurrent pregnancy loss by using formin-2 nucleic acids and polypeptides that have been identified to play a role in oocyte development.

## Claims

### Claim 1

A method for determining whether a patient has an increased risk for recurrent pregnancy loss, said method comprising determining whether a formin-2 gene of said patient has a mutation, wherein a mutation indicates that said patient has an increased risk for recurrent pregnancy loss.

### Claim 2

A method for determining whether a patient has an increased risk for recurrent pregnancy loss, said method comprising measuring formin-2 biological activity in said patient or in a cell from said patient, wherein decreased levels in said formin-2 biological activity, relative to normal levels, indicates that said patient has an increased risk for recurrent pregnancy loss.

### Claim 3

A method for determining whether a patient has an increased risk for recurrent pregnancy loss, said method comprising measuring formin-2 expression in said patient or in a cell from said patient, wherein decreased levels in said formin-2 expression relative to normal levels, indicates that said patient has an increased risk for recurrent pregnancy loss.

### Claim 4 (depends on 3)

The method of claim 3, wherein said formin-2 expression is determined by measuring levels of formin-2 polypeptide.

### Claim 5 (depends on 3)

The method of claim 3, wherein said formin-2 expression is determined by measuring levels of formin-2 RNA.

### Claim 6

A method for determining whether a person has an altered risk for recurrent pregnancy loss, comprising examining the person's formin-2 gene for polymorphisms, wherein the presence of a polymorphism associated with recurrent pregnancy loss indicates the person has an altered risk for recurrent pregnancy loss.